BioMérieux Buys Argene to Bolster Test Menu for Biocartis MDx Platform
July 21, 2011
BioMérieux Buys Argene to Bolster Test Menu for Biocartis MDx Platform
In addition, Argene will provide BioMérieux with a portfolio of molecular tests for diagnosing infectious diseases in transplant and other immunocompromised patients.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BioMérieux Buys Argene for up to $60.1M
July 19, 2011 / GenomeWeb Daily News - Biocartis Closes $41.3M Series B to Further Develop Molecular Dx Platform
April 8, 2010 / PCR Insider - Biocartis Buys Philips Molecular Dx Platform 'Inspired' by Consumer Electronics Tech
February 11, 2010 / PCR Insider - NIH Awards Akonni $300K to Develop System to ID Disease in CSF
August 4, 2011 / GenomeWeb Daily News - BioMérieux Buys ARGENE for $54M to Boost Virology-Testing Play
July 28, 2011 / The Sample